Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience

[11] Fossati N(2015)Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides Eur Urol 67 165-170

[12] Dell’Oglio P(2014)Pathological T0 following radical cystectomy with or without neo-adjuvant chemotherapy: a useful surrogate J Urol 191 898-906

[13] Grossman HB(2014)Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim support in muscle invasive urothelial cancer: pathologic, radiologic and biomarker correlates J Clin Oncol 32 1882-1894

[14] Natale RB(2016)Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: does dose intensity matter? Eur J Cancer 54 69-74

[15] Tangen CM(2005)Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 4602-4608

[16] Speights VO(2015)Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 67 241-249

[17] Vogelzand NJ(2015)Retrospective international study of cancers of the Urothelial tract (RISC) investigators. comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer Cancer 121 2586-2593

[18] Trump DL(2014)Accelerated methotrexate, vinblastine, doxorubicin and cisplatin is safe effective and efficient neoadjuvant treatment for muscle invasive bladder cancer results of a multicenter phase II study with molecular correlates of response and toxicity J Clin Oncol 32 1895-1901

[19] Yin M(2018)Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4a N0M0 bladder cancer treated with radical cystectomy J Urol 199 1452-1458

[20] Joshi M(2017)Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? Urologic Oncology: Seminars Original Investigations 35 e17-34.e25

[11] Fossati N(2015)Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides Eur Urol 67 165-170

[12] Dell’Oglio P(2014)Pathological T0 following radical cystectomy with or without neo-adjuvant chemotherapy: a useful surrogate J Urol 191 898-906

[13] Grossman HB(2014)Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim support in muscle invasive urothelial cancer: pathologic, radiologic and biomarker correlates J Clin Oncol 32 1882-1894

[14] Natale RB(2016)Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: does dose intensity matter? Eur J Cancer 54 69-74

[15] Tangen CM(2005)Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 4602-4608

[16] Speights VO(2015)Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 67 241-249

[17] Vogelzand NJ(2015)Retrospective international study of cancers of the Urothelial tract (RISC) investigators. comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer Cancer 121 2586-2593

[18] Trump DL(2014)Accelerated methotrexate, vinblastine, doxorubicin and cisplatin is safe effective and efficient neoadjuvant treatment for muscle invasive bladder cancer results of a multicenter phase II study with molecular correlates of response and toxicity J Clin Oncol 32 1895-1901

[19] Yin M(2018)Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4a N0M0 bladder cancer treated with radical cystectomy J Urol 199 1452-1458

[20] Joshi M(2017)Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? Urologic Oncology: Seminars Original Investigations 35 e17-34.e25